주식 발행 및 총 투표권
22 4월 2024
아박타 그룹 plc
("아박타" 또는 "그룹" 또는 "회사")
주식 발행 및 총 투표권
Avacta Group plc (AIM: AVCT), life sciences company developing innovative, targeted oncology drugs and powerful diagnostics today announces it has issued and allotted a total of 7,529,825 new ordinary shares of 10 pence each in the Company ("New Ordinary Shares"). The New Ordinary Shares are being issued in settlement of the quarterly principal of £2.55 million and interest repayment of £0.62 million in respect of the Company's unsecured convertible bonds (the "Convertible Bonds"), as detailed in Avacta's announcement on 18 October 2022.
The Board carefully considered the difficult balance between further dilution and the Group's cash resources to deliver key value adding milestones from the upcoming AVA6000 efficacy studies. On this occasion the Board has decided to settle the quarterly repayment in shares but will continue to review this on a quarterly basis and, if it considers that conditions allow, the repayment will be settled in cash.
After settlement of the quarterly repayment, the principal remaining under the Convertible Bonds will be reduced by £2.55 million to £35.70 million.
Under the terms and conditions of the Convertible Bonds, there is a reset of the conversion price on the date falling 18 months after their date of issue (i.e. on 20 April 2024, the "Reset Date") should the average Avacta share price over the 15-dealing-day period preceding the Reset Date(1) (the "15-Day Reset Average Market Price") be below the conversion price in effect on the Reset Date(2). In which case, the conversion price resets to the greater of (i) such 15-Day Reset Average Market Price and (ii) the reset price floor in effect on the Reset Date(3). The 15-Day Reset Average Market Price is 50.83 pence and, as such, with effect from the Reset Date of 20 April 2024, the conversion price was reset to 88.72 pence(4), subject as provided below.
If, during the 9-month period commencing on the Reset Date (i.e. during the period from 20 April 2024 to 20 January 2025, the "Reset Clawback Period"), the volume-weighted average price ("VWAP") of the Company's Ordinary Shares on each of at least 20 dealing days in any period of 30 consecutive dealing days is greater than 130% of the pre-reset conversion price(5) (the "Reference Conversion Price"), then the conversion price will be restored at such time to be equal to such Reference Conversion Price(5), thereby reversing the effect of the reset made on 20 April 2024.
Application has been made to AIM for the admission to trading of the 7,529,825 New Ordinary Shares resulting from the conversion, which is expected to occur at or around 8.00 am on 23 April 2024 ("Admission"). The New Ordinary Shares will rank pari passu with the existing Ordinary Shares of the Company.
승인 이후 회사의 확대 발행 주식 자본금은 359,042,104이 됩니다. 이 수치는 금융행위감독청(Financial Conduct Authority)의 규정에 따라 회사의 주식 자본에 대한 지분 또는 지분 변경을 통지해야 하는지 여부를 결정하는 계산의 분모로 회사 주주가 사용할 수 있습니다. 공개 지침 및 투명성 규칙.
(1) being calculated as the arithmetic average of the daily VWAPs of the Ordinary Shares during such 15-dealing-day period as aforesaid
(2) being 110.91 pence since the adjustment performed in accordance with the customary anti-dilution provisions contained in the terms and conditions of the Convertible Bonds following the Company's fundraise announced on 28 February 2024 (the conversion price was initially set at 118.75 pence at the time of issue of the Convertible Bonds)
(3) being 88.72 pence since the adjustment referred to in note (1) above (the reset price floor was initially set at 95 pence at the time of issue of the Convertible Bonds)
(4) from 110.91 pence immediately prior to the Reset Date
(5) being 110.91 pence, as may be adjusted during the Reset Clawback Period in accordance with the customary anti-dilution provisions contained in the terms and conditions of the Convertible Bonds
-끝-
Avacta Group plc의 추가 정보는 다음으로 연락하십시오.
아박타 그룹 plc Alastair Smith, 최고 경영자 토니 가디너 최고재무책임자(CFO) Michael Vinegrad, 그룹 커뮤니케이션 이사
| 전화 : + 44 (0) 1904 21 7070 www.아박타.com |
스티펠 니콜라우스 유럽 제한 (노마드 및 합작 기업 Broker) Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Ben Good
| 전화 : + 44 (0) 207 710 7600 www.stifel.com |
필헌트(공동기업) Broker) 제임스 스틸 / 크리스 골든 / 패트릭 버크홀름 | 전화 : + 44 (0) 207 418 8900 www.peelhunt.com
|
ICR Consilium(미디어 및 IR) 메리제인 엘리엇 / 제시카 호지슨 / 수카이나 비르지 |
Avacta Group plc 소개 - https://www.avacta.com
Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics.
Avacta has two divisions focused on therapeutics and diagnostics.
Avacta Therapeutics: a clinical stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs.
Avacta Diagnostics: focused on supporting healthcare professionals and broadening access to diagnostics.
Avacta has two proprietary platforms, pre|CISION™ and Affimer®.
The pre|CISION™ platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumours compared with healthy tissues. The pre|CISION™ platform harnesses this tumour specific protease to activate pre|CISION™ peptide drug conjugates and pre|CISION™ antibody/Affimer® drug conjugates in the tumour microenvironment, reducing systemic exposure and toxicity, allowing dosing to be optimised to deliver the best outcomes for patients.
The lead pre|CISION™ programme AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown a dramatic improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients.
이메일로 뉴스 알림을 등록하려면 다음으로 이동하십시오. https://avacta.com/investors/investor-news-email-alerts/
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.